Advertisement

Botulinum Neurotoxin Treatment of Unusual and Rare Painful Disorders

  • Bahman Jabbari

Abstract

Botulinum neurotoxins (BoNTs) can relieve painful muscle spasms through inhibition of acetylcholine release and alleviate neuropathic pain via blocking the release of pain mediators such as calcitonin gene-related peptide (CGRP), glutamate, substance P (SP), and others (detailed in Chap. 2). In addition to the common pain disorders discussed in the preceding chapters, data is now available on the possible efficacy of BoNTs in alleviating pain in uncommon and rare disorders.

In this chapter, three uncommon and rare conditions—stiff-person syndrome, painful legs–moving toes, and painful camptocormia—are discussed. The limited data from the literature about the use of BoNT in these conditions is presented. Case reports and video clips are included from the author’s experience to illustrate the clinical features and the technique of BoNT injection employed to relieve pain.

Keywords

Stiff-person syndrome Painful legs–moving toes Camptocormia Botulinum toxin Botulinum neurotoxin Onabotulinum toxin Abobotulinum toxin Incobotulinum toxin 

Supplementary material

Video 16.1

Case 16-1. Involuntary muscle contractions of the right rectus and vastus lateralis muscles in a patient with stiff-person syndrome (MOV 14081 kb)

Video 16.2

A patient with 10-year history of SPS and marked stiffness of the neck and shoulder muscles—onabotulinumtoxinA injections are given into the areas of local pain (MOV 85958 kb)

Video 16.3

Example of painful legs–moving toes (MOV 48703 kb)

Video 16.4

Example of painful legs–moving toes (MOV 5203 kb)

Video 16.5

Camptocormia in Parkinson’s disease

Video 16.6

Camptocormia: EMG guided injections into rectus and oblique abdominal muscle

Video 16.7

Camptocormia: Patient of video-16.6 interview after 4 cycles of treatment

References

  1. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG. Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord. 2008;23:2062–6.CrossRefPubMedGoogle Scholar
  2. Anagnostou E, Zambelis T. Botulinum toxin A in anti-GAD-positive stiff-limb syndrome. Muscle Nerve. 2012;46:457–8.CrossRefPubMedGoogle Scholar
  3. Arii Y, Sawada Y, Kawamura K, Miyake S, Taichi Y, Izumi Y, Kuroda Y, Inui T, Kaji R, Mitsui T. Immediate effect of spinal magnetic stimulation on camptocormia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85:1221–6.CrossRefPubMedGoogle Scholar
  4. Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65:355–9.CrossRefPubMedGoogle Scholar
  5. Bastin A, Gurmin V, Mediwake R, Gibbs J, Beynon H. Stiff man syndrome presenting with low back pain. Ann Rheum Dis. 2002;61:939–40.CrossRefPubMedCentralPubMedGoogle Scholar
  6. Bloch F, Houeto JL, Tezenas du Montcel S, Bonneville F, Etchepare F, Welter ML, Maisonobe T, Behar C, Lazennec JY, Kurys E, Arnulf I, Bonnet AM, Agid Y. Parkinson’s disease with camptocormia. J Neurol Neurosurg Psychiatry. 2006;77:1223–8.CrossRefPubMedCentralPubMedGoogle Scholar
  7. Blum P, Jankovic J. Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991;6:12–20.CrossRefPubMedGoogle Scholar
  8. Brodie BC. Pathological and surgical observations on the disease of the joints. London: Longman; 1818. p. 276.Google Scholar
  9. Ciccoto G, Blaya M, Kelley RE. Stiff person syndrome. Neurol Clin. 2013;31:319–28.CrossRefPubMedGoogle Scholar
  10. Colosimo C, Salvatori FM. Injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord. 2009;24:316–7.CrossRefPubMedGoogle Scholar
  11. Dalakas M, Rakocevic G, Dambrosia J. Double blind placebo-controlled study of rituximab in patients with stiff-person syndrome (SPS). Ann Neurol. 2009;66:S21.Google Scholar
  12. Davis D, Jabbari B. Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A. Mov Disord. 1993;8:371–3.CrossRefPubMedGoogle Scholar
  13. De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, Meinck HM, Austoni M, Fassetta G, Bottazzo G, Bates D, Cartlidge N, Solimena M, Kilimann MW. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med. 1993;178:2219–23.CrossRefPubMedGoogle Scholar
  14. Dressler D, Thompson PD, Gledhill RF, et al. The syndrome of painful legs and moving toes. Mov Disord. 1994;9:13–21.CrossRefPubMedGoogle Scholar
  15. Dupeyron A, Stober N, Gelis A, Castelnovo G, Labauge P, Pélissier J. Painful camptocormia: the relevance of shaking your patient’s hand. Eur Spine J. 2010;19 Suppl 2:S87–90.CrossRefPubMedGoogle Scholar
  16. Ebersbach G, Schelosky L, Schenkel A, Scholz U, Poewe W. Unilateral painful legs and moving toes syndrome with moving fingers – evidence for distinct oscillators. Mov Disord. 1998;13:965–8.CrossRefPubMedGoogle Scholar
  17. Eisa M, Singer C, Sengun C, Russel A, Jabbari B, Papapetropoulos S. Treatment of painful limbs/moving extremities with botulinum toxin type A injections. Eur Neurol. 2008;60:104–6.CrossRefPubMedGoogle Scholar
  18. Fekete R, Jankovic J. Childhood stiff-person syndrome improved with rituximab. Case Rep Neurol. 2012;4:92–6.CrossRefPubMedCentralPubMedGoogle Scholar
  19. Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord. 2009;24:2027–8.CrossRefPubMedGoogle Scholar
  20. Finsterer J, Strobl W. Presentation, etiology, diagnosis, and management of camptocormia. Eur Neurol. 2010;64:1–8.CrossRefPubMedGoogle Scholar
  21. Hadavi S, Noyce AJ, Leslie RD, Giovannoni G. Stiff person syndrome. Pract Neurol 2011;11: 272–82.Google Scholar
  22. Ho B, Prakash R, Morgan JC, Sethi KD. A case of levodopa-responsive camptocormia associated with advanced Parkinson’s disease. Nat Clin Pract Neurol. 2007;3:526–30.CrossRefPubMedGoogle Scholar
  23. Jabbari B, Molloy FM, Erickson M, Floeter MK. Bilateral painful hand-moving fingers: electrophysiological assessment of the central nervous system oscillator. Mov Disord. 2000;15:1259–63.CrossRefPubMedGoogle Scholar
  24. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54:614–23.CrossRefPubMedGoogle Scholar
  25. Kaji S, Shibayama H, Sato S, Fukutake T. Acute camptocormia as the presenting symptom of tetanus. J Neurol Neurosurg Psychiatry. 2014;85(8):936–7.CrossRefPubMedGoogle Scholar
  26. Liguori R, Cordivari C, Lugaresi E, Montagna P. Botulinum toxin A improves muscle spasms and rigidity in stiff-person syndrome. Mov Disord. 1997;12:1060–3.CrossRefPubMedGoogle Scholar
  27. Lyons M, Boucher O, Patel N, Birch B. Evidente Long-term benefit of bilateral subthalamic deep brain stimulation on camptocormia in Parkinson’s disease. Turk Neurosurg. 2012;22:489–92.PubMedGoogle Scholar
  28. Ma H, McEvoy KM, Milone M. Sporadic inclusion body myositis presenting with severe camptocormia. Clin Neurosci. 2013;20:1628–9.CrossRefGoogle Scholar
  29. Margraf NG, Wrede A, Rohr A, Schulz-Schaeffer WJ, Raethjen J, Eymess A, Volkmann J, Mehdorn MH, Jansen O, Deuschl G. Camptocormia in idiopathic Parkinson’s disease: a focal myopathy of the paravertebral muscles. Mov Disord. 2010;25:542–51.CrossRefPubMedGoogle Scholar
  30. McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69:230–8.CrossRefPubMedGoogle Scholar
  31. Melamed E, Djaldetti R. Camptocormia in Parkinson’s disease. J Neurol. 2006;253 Suppl 7:14–6. VII.Google Scholar
  32. Miyakawa T, Yoshimoto M, Takebayashi T, Yamashita T. Case reports: painful limbs/moving extremities: report of two cases. Clin Orthop Relat Res. 2010;468:3419–25.CrossRefPubMedCentralPubMedGoogle Scholar
  33. Moerch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome): report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin. 1956;31:421–7.Google Scholar
  34. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71:1955–8.CrossRefPubMedCentralPubMedGoogle Scholar
  35. Nathan PW. Painful legs and moving toes: evidence on the site of the lesion. J Neurol Neurosurg Psychiatry. 1978;41:934–9.CrossRefPubMedCentralPubMedGoogle Scholar
  36. Nguyen-Huu BK, Urban PP, Schreckenberger M, Dieterich M, Werhahn KJ. Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer. Mov Disord. 2006;21:1285–7.CrossRefPubMedGoogle Scholar
  37. Okuda Y, Suzuki K, Kitajima T, Masuda R, Asai T. Lumbar epidural block for ‘painful legs and moving toes’ syndrome: a report of three cases. Pain. 1998;78:145–7.CrossRefPubMedGoogle Scholar
  38. Oravivattanakul S, Abboud H, Fernandez H, Itin I. Unusual case of levodopa-responsive camptocormia in a patient with negative dopamine transporter scan and normal DYT 5 gene. Clin Neuropharmacol. 2014;37:63–4.CrossRefPubMedGoogle Scholar
  39. Pagano MB, Murinson BB, Tobian AA, King KE. Efficacy of therapeutic plasma exchange for treatment of stiff-person syndrome. Transfusion. 2014;54:1851–6.CrossRefPubMedGoogle Scholar
  40. Raju R, Hampe CS. Immunobiology of stiff-person syndrome. Int Rev Immunol. 2008;27:79–92.CrossRefPubMedGoogle Scholar
  41. Rakocevic G, Floeter MK. Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes. Muscle Nerve. 2012;45:623–34.CrossRefPubMedCentralPubMedGoogle Scholar
  42. Reese R, Knudsen K, Falk D, Mehdorn HM, Deuschl G, Volkmann J. Motor outcome of dystonic camptocormia treated with pallidal neurostimulation. Parkinsonism Relat Disord. 2014;20:176–9.CrossRefPubMedGoogle Scholar
  43. Reich SG. Painful legs and moving toes. Handb Clin Neurol. 2011;100:375–83.CrossRefPubMedGoogle Scholar
  44. Rodriguez RL, Fernandez HH. Sustained benefit of painful legs moving toes syndrome with botulinum toxin type A. J Clin Neurosci. 2013;20:1031–2.CrossRefPubMedGoogle Scholar
  45. Schoffer K. Painful leg moving toes treated with botulinum toxin type A: a video report. Mov Disord. 2010;25:784–5.CrossRefPubMedGoogle Scholar
  46. Schott GD. “Painful legs and moving toes:” the role of trauma. J Neurol Neurosurg Psychiatry. 1981;44:344–6.CrossRefPubMedCentralPubMedGoogle Scholar
  47. Sevy A, Franques J, Chiche L, Pouget J, Attarian S. Successful treatment with rituximab in a refractory Stiff-person syndrome. Rev Neurol (Paris). 2012;168:375–8.CrossRefGoogle Scholar
  48. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med. 1990;322:1555–60.CrossRefPubMedGoogle Scholar
  49. Souques A, Rosanoff-Saloff M. La camptocormie. Incurvation du tronc consécutive aux traumatismes du dos et des lombes. Considérations morphologiques. Société de neurologie de Paris, seance du 4 novembre. Rev Neurol 1914;15:937–9.Google Scholar
  50. Spillane JD, Nathan PW, Kelly RE, Massden CD. Brain. 1971;94:541–56.Google Scholar
  51. Takahashi H, Saitoh C, Iwata O, Nanbu T, Takada S, Morita S. Epidural spinal cord stimulation for the treatment of painful legs and moving toes syndrome. Pain. 2002;96:343–5.CrossRefPubMedGoogle Scholar
  52. von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord. 2008;23:889–92.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bahman Jabbari
    • 1
  1. 1.Botulinum Toxin Treatment ProgramYale School of MedicineNew HavenUSA

Personalised recommendations